CSPC Innovation Pharmaceutical Co., Ltd.

SZSE:300765 Stock Report

Market Cap: CN¥40.4b

CSPC Innovation Pharmaceutical Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Feng Han

Chief executive officer

CN¥813.7k

Total compensation

CEO salary percentagen/a
CEO tenure1.8yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure1.8yrs

Recent management updates

Recent updates

Investor Optimism Abounds CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) But Growth Is Lacking

Jan 16
Investor Optimism Abounds CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) But Growth Is Lacking

Are CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) Investors Paying Above The Intrinsic Value?

Nov 21
Are CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) Investors Paying Above The Intrinsic Value?

Why CSPC Innovation Pharmaceutical's (SZSE:300765) Shaky Earnings Are Just The Beginning Of Its Problems

Oct 31
Why CSPC Innovation Pharmaceutical's (SZSE:300765) Shaky Earnings Are Just The Beginning Of Its Problems

Earnings Tell The Story For CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) As Its Stock Soars 27%

Sep 30
Earnings Tell The Story For CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) As Its Stock Soars 27%

Estimating The Fair Value Of CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765)

Aug 16
Estimating The Fair Value Of CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765)

CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) 27% Share Price Plunge Could Signal Some Risk

Jul 04
CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) 27% Share Price Plunge Could Signal Some Risk

CSPC Innovation Pharmaceutical's (SZSE:300765) Weak Earnings May Only Reveal A Part Of The Whole Picture

Apr 29
CSPC Innovation Pharmaceutical's (SZSE:300765) Weak Earnings May Only Reveal A Part Of The Whole Picture

CSPC Innovation Pharmaceutical (SZSE:300765) Will Pay A Larger Dividend Than Last Year At CN¥0.32

Apr 25
CSPC Innovation Pharmaceutical (SZSE:300765) Will Pay A Larger Dividend Than Last Year At CN¥0.32

CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) P/E Still Appears To Be Reasonable

Apr 24
CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) P/E Still Appears To Be Reasonable

CEO

Feng Han (50 yo)

1.8yrs

Tenure

CN¥813,700

Compensation

Mr. Feng Han is GM & Director of CSPC Innovation Pharmaceutical Co., Ltd. from April 07, 2023.

Board Members

NamePositionTenureCompensationOwnership
Feng Han
GM & Director1.8yrsCN¥813.70kno data
Weidong Pan
Chairman7.2yrsno datano data
Huaiyu Wang
Non-Independent Director7.2yrsno data0.0013%
CN¥ 512.7k
Lei Cai
Non-Independent Director1.8yrsno datano data
Dong Yang
Non-Independent Director1.8yrsno datano data
Bing Yao
Non-Independent Director1.8yrsno datano data
Dibin Li
Independent Director1.8yrsCN¥45.00kno data
Peng Yang
Independent Director1.8yrsCN¥45.00kno data
Congzhi Di
Independent Director1.8yrsCN¥45.00kno data
Ling Zhang
Non-Employee Supervisor1.8yrsno datano data
Jiyong Zhang
Non-Employee Supervisor1.8yrsno datano data
Bing Yuan
Employee Supervisor4.8yrsno datano data

1.8yrs

Average Tenure

49.5yo

Average Age

Experienced Board: 300765's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 15:31
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CSPC Innovation Pharmaceutical Co., Ltd. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shitong HanCitic Securities Co., Ltd.
null nullCLSA
Zhijie ZhaoCLSA